Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: UNIM-004-oral and UNIM-005-Topical: UNIM 004(Oral): 2 Tabs of 500 mg. each two times in a day
UNIM 005 (Topical): will apply over the lesions in sufficient quantity as per the area of l
Sponsors
Central Council for research in Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: Patients with clinically diagnosed non-dermatomal progressive vitiligo 18-50 years of Age Any gender With any duration of disease, site, extension and distribution of lesions Willingness to written informed consent form
Exclusion criteria
Exclusion criteria: Patients having Dermatomal vitiligo Pregnant and lactating mother Patients having hepato-renal, cardiac and pulmonary disorders Patients on active vitiligo treatment with other drugs Subjects with other skin disease having known allergies Subjects those who are unwilling to come regular follow ups for the entire duration of study Non-cooperative patients / Non treatment compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This Study could be validate the efficacy of Unani drug scientifically by using specific biomarkers of the disease.Timepoint: 3 Years | — |
Secondary
| Measure | Time frame |
|---|---|
| The obtained results would be useful for further disease association studiesTimepoint: 3 years | — |
Countries
India
Contacts
Public ContactDr Tasleem Ahmad
National Research Institute of Unani Medicinefor skin disorders
Outcome results
None listed